Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: AUPH

Aurinia Pharmaceuticals Inc.

Healthcare | Biotechnology

No licensed closing price on file for AUPH. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$2.29

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:15 UTC.

What Aurinia Pharmaceuticals Inc. does

Aurinia is a biopharmaceutical company that develops and sells therapies for autoimmune diseases with high unmet medical needs. The company's primary product is LUPKYNIS (voclosporin), introduced in January 2021 as the first FDA-approved oral therapy for treating adult patients with active lupus nephritis. Aurinia sells LUPKYNIS directly in the United States through its own commercial organization and to specialty pharmacies and distributors, while its collaboration partner Otsuka markets and sells LUPKYNIS in Japan, the European Union, the United Kingdom, and Switzerland.

Summarized from Aurinia Pharmaceuticals Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$2.29
Return on equity49.40%

Revenue, margins & earnings

FY2021: net loss $181M on revenue $46M$46MFY2021FY2022: net loss $108M on revenue $134M$134MFY2022FY2023: net loss $78M on revenue $176M$176MFY2023FY2024 Revenue: $235M — margin split not shown (non-operating gains)$235MFY2024FY2025 Revenue: $283M — margin split not shown (non-operating gains)FY2025: net income $287M exceeded revenue $283M by $4M — non-operating gains (e.g. asset sales), not operating profit$283MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-11
  • 2026-09-11Chief Legal OfficerSale-11,939$190.4K
  • 2026-08-25Chief Legal OfficerSale-20,975$355.9K
  • 2026-06-08DirectorDirector Stock Option (right to buy)Award23,931—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Aurinia Pharmaceuticals Inc. do?

Aurinia is a biopharmaceutical company that develops and sells therapies for autoimmune diseases with high unmet medical needs.

When did AUPH last file with the SEC?

Aurinia Pharmaceuticals Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:15 UTC. This page is also available as JSON at /api/data?ticker=AUPH and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AUPH and 5,000+ tickers.

Create a free account — keep AUPH
For your agent
GET /api/data?ticker=AUPH

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt